Application of Rivaroxaban in Patients with Non-valvular Atrial Fibrillation and End-stage Kidney Disease: A Systematic Review and Meta-analysis

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2023 Feb 27

PMID 36844734

Authors

Zhenzhen Yang

Jieya Wang

Ye Yuan

Tian Cheng

Feifei Ren

Songsong Wang

Zhiqing Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Nowadays, the number of patients with non-valvular atrial fibrillation (NVAF) complicated by end-stage renal disease (ESKD) is increasing. There are significant challenges in anticoagulation with prescription drugs because of the high risk of bleeding and embolism among these patients. However, no randomized controlled trials (RCTs) of warfarin in combination with any non-vitamin K oral anticoagulant (NOACs) have been performed in patients with baseline creatinine clearance (CrCl) <25 ml/min, which makes it difficult to justify the use of anticoagulants in such patients. Then, we aimed to collect and summarize all evidence to enable the anticoagulation of rivaroxaban, which is less cleared by the kidneys, in patients with severe renal insufficiency and to complement and improve the evidence on the use of rivaroxaban for anticoagulation.

Methods: The present systematic review and meta-analysis searched the databases of , , the , , , and for relevant studies from inception to 1 June 2022, with the restriction of English and Chinese. Eligible cohort studies and RCTs that reported efficacy outcomes [composite of stroke and systemic embolism (SSE), ischemic stroke (ICS), and systemic embolization] or safety outcomes [major bleeding, intracranial hemorrhage (ICH), and gastrointestinal bleeding (GIB)] of rivaroxaban in NVAF patients with ESKD were enrolled. Two authors completed the data extraction and quality assessment work, respectively. The Cochrane Collaboration tool for assessing the risk of bias was used for RCTs, and the NEW-Castle Ottawa scale was used for study quality assessment for cohort studies. Dichotomous variables were calculated as risk factors with 95% confidence intervals (CIs), and meta-analysis was performed to probe the effect of research design, rivaroxaban dose, and controlled drug factors on outcomes.

Results: In total, three studies were included for meta-analysis, involving 6,071 NVAF patients with ESKD, and two studies were included for qualitative analysis. All included studies were at low risk of bias. A meta-analysis demonstrated that mix-dose rivaroxaban caused no statistical discrepancy in the occurrence of thrombotic and bleeding events when compared to the control group (embolism, LogOR: -0.64, 95% CI: -1.05 to -0.23, P:0.25; bleeding, LogOR: -0.33, 95% CI: -0.63 to -0.03, P:0.15), and low-dose rivaroxaban produced similar results (embolism, LogOR: -1.04, 95% CI: -2.15 to 0.07, P:0.61; bleeding, LogOR: -0.81, 95% CI: -1.19 to -0.44, P:0.93).

Conclusion: In this study, low-dose rivaroxaban (10 mg, once a day) may benefit more than warfarin in patients with NVAF and ESKD.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero/#recordDetails, identifier CRD42022330973.

References

Chan K, Lazarus J, Thadhani R, Hakim R . Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009; 20(10):2223-33. PMC: 2754104. DOI: 10.1681/ASN.2009030319. View

Ma Y, Zhang Y, Qiu C, He C, He T, Shi S . Rivaroxaban Suppresses Atherosclerosis by Inhibiting FXa-Induced Macrophage M1 Polarization-Mediated Phenotypic Conversion of Vascular Smooth Muscle Cells. Front Cardiovasc Med. 2021; 8:739212. PMC: 8634446. DOI: 10.3389/fcvm.2021.739212. View

Genovesi S, Pogliani D, Faini A, Valsecchi M, Riva A, Stefani F . Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis. 2005; 46(5):897-902. DOI: 10.1053/j.ajkd.2005.07.044. View

Dias C, Moore K, Murphy J, Ariyawansa J, Smith W, Mills R . Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis. Am J Nephrol. 2016; 43(4):229-36. DOI: 10.1159/000445328. View

Benjamin E, Muntner P, Alonso A, Bittencourt M, Callaway C, Carson A . Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019; 139(10):e56-e528. DOI: 10.1161/CIR.0000000000000659. View

Abdelbaky A, Corsini E, Figueroa A, Fontanez S, Subramanian S, Ferencik M . Focal arterial inflammation precedes subsequent calcification in the same location: a longitudinal FDG-PET/CT study. Circ Cardiovasc Imaging. 2013; 6(5):747-54. DOI: 10.1161/CIRCIMAGING.113.000382. View

Kubitza D, Becka M, Mueck W, Halabi A, Maatouk H, Klause N . Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2010; 70(5):703-12. PMC: 2997310. DOI: 10.1111/j.1365-2125.2010.03753.x. View

Siontis K, Zhang X, Eckard A, Bhave N, Schaubel D, He K . Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation. 2018; 138(15):1519-1529. PMC: 6202193. DOI: 10.1161/CIRCULATIONAHA.118.035418. View

Hagii J, Tomita H, Metoki N, Tamai Y, Saito S, Shiroto H . Effect of rivaroxaban on prothrombin fragment 1+2 compared with warfarin in patients with acute cardioembolic stroke: Insight from its serial measurement. Thromb Res. 2016; 148:9-14. DOI: 10.1016/j.thromres.2016.10.011. View

10.

van Zyl M, Abdullah H, Noseworthy P, Siontis K . Stroke Prophylaxis in Patients with Atrial Fibrillation and End-Stage Renal Disease. J Clin Med. 2020; 9(1). PMC: 7019832. DOI: 10.3390/jcm9010123. View

11.

Patel M, Mahaffey K, Garg J, Pan G, Singer D, Hacke W . Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883-91. DOI: 10.1056/NEJMoa1009638. View

12.

January C, Samuel Wann L, Calkins H, Chen L, Cigarroa J, Cleveland Jr J . 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the.... Circulation. 2019; 140(2):e125-e151. DOI: 10.1161/CIR.0000000000000665. View

13.

Brodsky S, Satoskar A, Chen J, Nadasdy G, Eagen J, Hamirani M . Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases. Am J Kidney Dis. 2009; 54(6):1121-6. DOI: 10.1053/j.ajkd.2009.04.024. View

14.

Mavrakanas T, Samer C, Nessim S, Frisch G, Lipman M . Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. J Am Soc Nephrol. 2017; 28(7):2241-2248. PMC: 5491286. DOI: 10.1681/ASN.2016090980. View

15.

Miao B, Sood N, Bunz T, Coleman C . Rivaroxaban versus apixaban in non-valvular atrial fibrillation patients with end-stage renal disease or receiving dialysis. Eur J Haematol. 2020; 104(4):328-335. DOI: 10.1111/ejh.13383. View

16.

Yang F, Chou D, Schweitzer P, Hanon S . Warfarin in haemodialysis patients with atrial fibrillation: what benefit?. Europace. 2010; 12(12):1666-72. DOI: 10.1093/europace/euq387. View

17.

See L, Lee H, Chao T, Li P, Liu J, Wu L . Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis. Cardiovasc Drugs Ther. 2020; 35(5):975-986. DOI: 10.1007/s10557-020-07108-4. View

18.

De Vriese A, Caluwe R, Van Der Meersch H, De Boeck K, De Bacquer D . Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial. J Am Soc Nephrol. 2021; 32(6):1474-1483. PMC: 8259651. DOI: 10.1681/ASN.2020111566. View

19.

Coleman C, Kreutz R, Sood N, Bunz T, Eriksson D, Meinecke A . Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis. Am J Med. 2019; 132(9):1078-1083. DOI: 10.1016/j.amjmed.2019.04.013. View

20.

El-Abbadi M, Giachelli C . Mechanisms of vascular calcification. Adv Chronic Kidney Dis. 2007; 14(1):54-66. DOI: 10.1053/j.ackd.2006.10.007. View